A Study of NT-175 in Adult Subjects with Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Exclusion Criteria

• - Any another primary malignancy within the 3 years prior to enrollment (except for non-melanoma skin cancer, carcinoma in situ (eg, cervix, bladder, breast) or low-grade prostate cancer
• - Known, active primary central nervous system (CNS) malignancy
• - History of prior adoptive cell and gene therapy, allogeneic stem cell transplant or solid organ transplantation.
• - History of stroke or transient ischemic attack within the 12 months prior to enrollment.
• - History of clinically significant cardiac disease within the 6 months prior to enrollment or heart failure at any time prior to enrollment.
• - Systemic therapy within at least 2 weeks or 3 half-lives, whichever is shorter, prior to enrollment.
• - History of severe immediate hypersensitivity reaction to cyclophosphamide, fludarabine, or rIL-2; or known sensitivity or allergy to methotrexate, gentamicin, or other aminoglycosides.
• - Any form of primary immunodeficiency.
• - Live vaccine ≤ 4 weeks prior to enrollment or plans to have a live vaccine prior to planned lymphodepleting chemotherapy and/or NT-175 treatment.
• - Active immune-mediated disease requiring systemic steroids or other immunosuppressive treatment (except if related to prior checkpoint inhibitor therapy)
• - Female of childbearing potential who is lactating or breast feeding at the time of enrollment.
• - Known to have Li-Fraumeni syndrome or is known to have relatives who are diagnosed with Li-Fraumeni syndrome.